-
Pfizer To Buy InnoPharma, Acquires Injectables Portfolio
7/17/2014
Pfizer announced that it has agreed to acquire privately-held pharmaceutical development firm InnoPharma.
-
GSK, Codexis Announce $25M Tech And License Partnership
7/17/2014
Biocatalyst developer Codexis announced that it has signed into a platform technology license agreement with pharmaceutical firm GlaxoSmithKline.
-
EU Launches Initiative To Fast Track Next Gen Drugs
7/14/2014
The second Innovative Medicines Initiative (IMI 2) has been launched in Europe with the aim of fast-tracking development of next generation drugs, particularly those targeting unmet medical needs. The 3.3 billion euro IMI 2 Strategic Research Agenda will also promote quicker patient access to new drugs.
-
Regeneron And Sanofi Post Positive Phase 2B Data For Dupilumab In AD
7/11/2014
Regeneron Pharmaceuticals and its partner Sanofi posted positive results from a dose-ranging Phase 2B trial of dupilumab for the treatment of atopic dermatitis (AD).
-
Purdue Pharma's HYD Pain Drug Receives FDA Priority Review
7/10/2014
The U.S. Food and Drug Administration (FDA) has granted Priority Review to Purdue Pharma’s once-daily hydrocodone bitartrate tablet (HYD) with abuse-deterrent properties.
-
Lilly And Yabao Ink Agreement To Co-Develop Diabetes Therapy
7/10/2014
Chinese pharmaceutical company Yabao Pharmaceutical and Eli Lilly announced that they have entered into a strategic partnership to co-develop Lilly’s lead diabetes treatment.
-
Novartis Begins Flu Vaccine Shipments To U.S. For 2014-2015 Season
7/8/2014
Last week, Swiss pharmaceutical company Novartis announced that it has initiated shipment of its seasonal influenza vaccines to the U.S. market for the 2014-2015 flu season. The company said it plans to ship a minimum of 30 million doses of its vaccines Fluvirin and Flucelvax.
-
Bayer Allies With University Of Oxford In Gynecological Therapies
7/8/2014
Bayer announced that it has entered into partnership with the University of Oxford for the development of new gynecological therapies, particularly in the area of endometriosis and uterine fibroids.
-
Roche's Genentech To Acquire Seragon Pharmaceuticals
7/3/2014
Roche announced that Roche Group member Genentech has signed into a definitive agreement to acquire privately-held biotech firm Seragon Pharmaceuticals and its Phase I program which is currently developing a new approach for breast cancer.
-
Jazz To Acquire Rights To Sigma-Tau's Defibrotide
7/3/2014
Jazz Pharmaceuticals announced that it has signed into a definitive agreement to acquire defibrotide from Sigma-Tau Pharmaceuticals. Jazz will accomplish the transaction through its subsidiary Gentium, which it acquired earlier this year, and the rights will be applicable in the Americas and in the U.S.